Rosenblum Silverman Sutton S F Inc Alnylam Pharmaceuticals, Inc. Transaction History
Rosenblum Silverman Sutton S F Inc
- $364 Million
- Q2 2024
A detailed history of Rosenblum Silverman Sutton S F Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Rosenblum Silverman Sutton S F Inc holds 35,200 shares of ALNY stock, worth $9.64 Million. This represents 2.35% of its overall portfolio holdings.
Number of Shares
35,200
Previous 35,470
0.76%
Holding current value
$9.64 Million
Previous $5.3 Million
61.38%
% of portfolio
2.35%
Previous 1.54%
Shares
16 transactions
Others Institutions Holding ALNY
# of Institutions
638Shares Held
108MCall Options Held
2.33MPut Options Held
2.15M-
Capital World Investors Los Angeles, CA15MShares$4.1 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.43 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.62 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.7 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.65 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...